Recently, preclinical mechanistic studies suggested that the treatment via combining CSF-1R inhibition (e.g., via BLZ-945) with RT can enhance RT-induced antitumor immunity and lead to long-term improvement in outcomes in murine gliomas. Here, CSF1R is linked to glioma.